How does Project 2025 plan to restrict access to abortion, and what are the implications for women’s health rights?
Project 2025 proposes stringent measures to restrict access to abortion medications, specifically targeting mifepristone.
The plan includes reversing FDA approval for such drugs, reinstating previous safety protocols mostly eliminated in 2016, and enforcing restrictions like limiting the use of abortion pills to 49 days of gestation.
Additionally, it requires in-person dispensing and mandates prescribers to report all serious adverse events.
Direct Text Citation:
“Reinstate earlier safety protocols for Mifeprex… limit abortion pills to 49 days gestation.” (Project 2025, pages 490-491).
Implication:
These changes signify a significant tightening of regulations around abortion drugs, potentially making it much harder for women to access necessary medication for safe and early abortion care. This could lead to increased health risks as women might seek later-term or less safe procedures, or be forced to carry unwanted pregnancies due to reduced access to these medications.